It has been demonstrated that mutant KRAS pancreatic cancer cell lines treated with chemotherapy activate MAPK and NF-κB pathways, inducing the secretion of inflammatory cytokines able to enhance monocyte differentiation towards MDSCs and thus counteracting therapy response (120). This evidence concerns the gene KRAS and pancreatic neoplasm.